

128. Saeki H, Ito T, Hayashi M, et al. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. *J Eur Acad Dermatol Venereol.* 2015;29:1653-1655.
129. Pappas V, Rallis E, Kirsten L, Kyriakis K. Ustekinumab for the treatment of HIV psoriasis. *J Dermatolog Treat.* 2012;23:398-399.
130. Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. *Am J Respir Crit Care Med.* 2008;177:348-355.
131. Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. *N Engl J Med.* 2011;364:1441-1448.
132. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. *J Am Acad Dermatol.* 2008;59:209-217.
133. Amerio P, Amoroso G, Bardazzi F, et al. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. *J Dermatolog Treat.* 2013;24:305-311.
134. di Girolamo C, Pappone N, Melillo E, Rengo C, Giuliano F, Melillo G. Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy. *Br J Rheumatol.* 1998;37:1136-1137.
135. Binyamin K, Cooper RG. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. *Rheumatology (Oxford).* 2001;40:341-342.
136. Smith JD, Knox JM. Psoriasis, methotrexate and tuberculosis. *Br J Dermatol.* 1971;84:590-593.
137. Sundaram M, Adhikary SD, John GT, Kekre NS. Tuberculosis in renal transplant recipients. *Indian J Urol.* 2008;24:396-400.
138. John GT, Shankar V. Mycobacterial infections in organ transplant recipients. *Semin Respir Infect.* 2002;17:274-283.
139. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. *Lancet.* 1994;344:423-428.
140. Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. *Best Pract Res Clin Rheumatol.* 2006;20:757-790.
141. Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. *Arthritis Rheum.* 2007;57:756-761.
142. Culver EL, Travis SP. How to manage the infectious risk under anti-TNF in inflammatory bowel disease. *Curr Drug Targets.* 2010;11:198-218.
143. Mariette X, Vencovsky J, Lortholary O, et al. The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region. *RMD Open.* 2015;1:e000044.
144. Kay J, Fleischmann R, Keystone E, et al. Five-year safety data from 5 clinical trials of subcutaneous golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. *J Rheumatol.* 2016;43:2120-2130.
145. Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. *Br J Dermatol.* 2012;167:1145-1152.

Answers to CME examination

Identification No. JD0119

January 2019 issue of the Journal of the American Academy of Dermatology.

Kaushik SB, Lebwohl MG. *J Am Acad Dermatol* 2019;80:43-53.

- 1.b
- 2.d